The results demonstrated that treatment with pharmacological CDK9 inhibitor alleviated atherosclerosis by reducing CDK9 phosphorylation and then inhibiting inflammation and phenotypic switching of VSMCs. The gene discussed is CDK9; the disease is atherosclerosis.